secwatch.observer — SEC 8-K summary
======================================

Issuer:     Terns Pharmaceuticals, Inc. (TERN)
CIK:        0001831363
Form:       8-K
Filed at:   2024-04-29T23:59:59+00:00
Accession:  0000950170-24-049870
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Terns reports TERN-701 Phase 1 PK data: no food effect, once-daily dosing supported
--------------------------------------------------------------------------------

- TERN-701 showed no clinically significant food effect at 80 mg; supports dosing with or without food.
- PK linear across 20-160 mg; median half-life 8-12 hours; exposures at 80 and 160 mg met predicted efficacious levels.
- Phase 1 CARDINAL trial in 2L+ CML ongoing; interim dose escalation data expected H2 2024.
- No clinically meaningful changes in lab data, vital signs, or ECG across all dose levels.
- Data consistent with Chinese Phase 1 study; plans to present at upcoming scientific conference.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831363/000095017024049870/0000950170-24-049870-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831363/000095017024049870/tern-20240429.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-049870

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer